Genentech
Roche’s TIGIT Therapy: ESMO Reveals Ongoing Commitment
Roche is taking a steadfast position in the realm of TIGIT-class therapies, even in the face of fluctuating data and ...
PTC sells royalty rights of SMA drug Evrysdi to Royalty Pharma for $1.5B
As part of its cost-cutting efforts and in response to potential challenges in the European market, PTC Therapeutics is taking ...
Biogen hires Grogan as R&D head, aims to boost innovation and agility
Dr. Jane Grogan, who recently assumed her role as the head of research at Biogen, is eager to bring the ...
Roche wins patent appeal over Hemlibra, its hemophilia A drug, against Takeda’s Baxalta
In a patent dispute revolving around two competing hemophilia medications, Roche’s Genentech unit has achieved its second consecutive victory. Following ...
Genentech and PeptiDream expand peptide collaboration to explore radiopharmaceuticals for cancer
Japanese biotech firm PeptiDream continues to attract significant interest from major pharmaceutical companies. Genentech, a long-term partner, has entered into ...
Genentech and Orionis Biosciences team up to discover molecular glue drugs for oncology and neurodegeneration
Genentech, a subsidiary of Roche, is aggressively expanding its partnered portfolio into cutting-edge areas of research and development. Following a ...
Genentech was fined $158K by the EPA for improper management of hazardous waste at a site in San Francisco
After reaching an agreement with the US Environmental Protection Agency (EPA) to address environmental violations at a former facility, Genentech ...
